Key Takeaways
- Liraglutide is a daily injectable GLP-1 receptor agonist sold as Victoza for type 2 diabetes (1.8 mg) and Saxenda for chronic weight management (3.0 mg).
- It mimics the gut hormone GLP-1 and lasts about 24 hours per injection.
- It was the first long-acting GLP-1 medication approved for obesity, in 2014.
- Liraglutide is a 31-amino-acid peptide that's structurally almost identical to native human GLP-1, with one critical modification: a 16-carbon fatty acid chain attached via a glutamate spacer at position 26.
- That fatty acid lets liraglutide bind to albumin in blood, creating a slow-release reservoir that extends its half-life from 2 minutes (native GLP-1) to about 13 hours.
Direct answer (40-60 words, snippet-optimized)
Liraglutide is a daily injectable GLP-1 receptor agonist sold as Victoza for type 2 diabetes (1.8 mg) and Saxenda for chronic weight management (3.0 mg). It mimics the gut hormone GLP-1 and lasts about 24 hours per injection. It was the first long-acting GLP-1 medication approved for obesity, in 2014.
Table of contents
- The 30-second answer
- What liraglutide is and how it was developed
- Liraglutide brand names: Victoza vs Saxenda
- The mechanism: how a fatty acid creates a 24-hour drug
- The clinical data: how much A1C, how much weight
- Dosing schedule for both indications
- Side effects and the titration schedule
- Liraglutide vs semaglutide vs tirzepatide
- Who should and shouldn't take liraglutide
- Cost, generics, and savings programs
- What happens when you stop
- FAQ
- Footer disclaimers
What liraglutide is and how it was developed
Liraglutide is a 31-amino-acid peptide that's structurally almost identical to native human GLP-1, with one critical modification: a 16-carbon fatty acid chain attached via a glutamate spacer at position 26. That fatty acid lets liraglutide bind to albumin in blood, creating a slow-release reservoir that extends its half-life from 2 minutes (native GLP-1) to about 13 hours.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Novo Nordisk developed the molecule through a research program in the late 1990s and early 2000s. Liraglutide was first approved by the European Medicines Agency in 2009 and by the FDA in 2010 as Victoza for type 2 diabetes. In 2014, the FDA approved a higher-dose version (Saxenda, 3.0 mg) for chronic weight management.
Liraglutide was the first GLP-1 receptor agonist to last more than a few hours per dose. It's still in regular use, but the introduction of weekly options (Trulicity in 2014, Ozempic in 2017, Wegovy in 2021) changed the practical economics. A weekly injection beats a daily one for most patients. Liraglutide held the obesity-medication category alone for 7 years before Wegovy arrived.
Liraglutide brand names: Victoza vs Saxenda
The same molecule is sold under two brand names with different dose strengths and different FDA-approved indications.
| Brand | Active ingredient | Max dose | FDA indication | Manufacturer |
|---|---|---|---|---|
| Victoza | Liraglutide | 1.8 mg/day | Type 2 diabetes (adults and pediatric ≥10) | Novo Nordisk |
| Saxenda | Liraglutide | 3.0 mg/day | Chronic weight management in adults (BMI ≥30, or ≥27 with comorbidity) and adolescents (12+, BMI ≥95th percentile) | Novo Nordisk |
The brands differ only in maximum dose and indication. The mechanism is identical. The titration speed is similar. The side-effect profile is similar but tends to be more pronounced at the higher Saxenda dose.
A patient prescribed Victoza for diabetes is generally not interchangeable with Saxenda; the prescription specifies the indication and dose. Some patients with both diabetes and obesity may use one or the other depending on the primary clinical goal.
The mechanism: how a fatty acid creates a 24-hour drug
Native GLP-1 has a 2-minute half-life because the enzyme DPP-4 cleaves it almost immediately and the kidney filters out the fragments. To make a long-acting drug, scientists had to solve both problems.
Liraglutide solves them with two changes:
- An amino-acid substitution at position 8 that reduces DPP-4 cleavage by about 95%.
- A C16 fatty acid chain attached via a glutamate spacer at position 26 that lets the molecule bind reversibly to albumin (the most abundant protein in blood, 50% of plasma protein). Bound to albumin, liraglutide is too big to filter out through the kidney and is protected from enzymatic breakdown.
The result is a 13-hour half-life and a 24-hour duration of action. The injection is given once daily, ideally at the same time each day.
Compare this to semaglutide (Ozempic, Wegovy), which uses a different fatty acid attachment and additional modifications to push the half-life to 7 days. Each generation of GLP-1 design has bought more duration from similar engineering tricks.
The clinical data: how much A1C, how much weight
The published data on liraglutide is some of the most extensive in the GLP-1 class because the drug has been on the market longer.
Type 2 diabetes (LEAD program, multiple trials, ~6,000 patients combined):
| Trial | Comparator | Liraglutide A1C reduction | Liraglutide weight loss |
|---|---|---|---|
| LEAD-1 | Glimepiride | -1.1% | -2.4 kg |
| LEAD-2 | Glimepiride | -1.0% | -2.8 kg |
| LEAD-5 | Insulin glargine | -1.3% | -1.8 kg |
Cardiovascular outcomes (LEADER, Marso et al., NEJM 2016, N=9,340): Patients with type 2 diabetes and high cardiovascular risk had a 13% reduction in major adverse cardiovascular events on liraglutide vs placebo over a median 3.8 years.
Obesity (SCALE program, multiple trials, ~5,000 patients combined):
| Trial | Population | Mean weight loss (liraglutide 3.0 mg) | Mean weight loss (placebo) |
|---|---|---|---|
| SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015) | BMI ≥30 or ≥27 with comorbidity | -8.0% | -2.6% |
| SCALE Diabetes | T2D, BMI ≥27 | -6.0% | -2.0% |
| SCALE Maintenance | Post low-calorie diet | -6.2% | -0.2% |
The headline numbers: about 5 to 8% body weight loss at 56 weeks on liraglutide 3.0 mg, compared to 12 to 15% on weekly semaglutide 2.4 mg or 15 to 22% on tirzepatide. Liraglutide is real but smaller in magnitude than its successors.
Dosing schedule for both indications
Victoza (type 2 diabetes) titration:
- Week 1: 0.6 mg subcutaneous daily
- Week 2: 1.2 mg subcutaneous daily
- Week 3+: 1.8 mg subcutaneous daily (maintenance)
The 0.6 mg starting dose is intended for tolerability, not efficacy. It's standard to titrate upward each week as tolerated.
Saxenda (obesity) titration:
- Week 1: 0.6 mg subcutaneous daily
- Week 2: 1.2 mg subcutaneous daily
- Week 3: 1.8 mg subcutaneous daily
- Week 4: 2.4 mg subcutaneous daily
- Week 5+: 3.0 mg subcutaneous daily (maintenance)
The slower escalation (5 weeks vs 3 weeks for Victoza) reflects the higher maintenance dose. Patients who can't tolerate the next step should hold at the current dose rather than push through.
Injection sites: Abdomen, thigh, or upper arm. Rotate sites to reduce lipohypertrophy. Inject at the same time each day for consistent levels.
Missed doses: If you miss a dose by less than 12 hours, take it as soon as remembered. If more than 12 hours, skip the dose and resume the next day. Don't double up. If you miss for more than 3 consecutive days, restart at 0.6 mg and titrate again.
Side effects and the titration schedule
The titration schedule exists because the side-effect profile is meaningful at full dose for many patients.
Very common (≥10%):
- Nausea (30 to 40% of patients during titration)
- Diarrhea
- Constipation
- Vomiting
- Headache
Common (1 to 10%):
- Dyspepsia
- Decreased appetite (the desired effect, but uncomfortable for some)
- Fatigue
- Injection-site reactions
- Hypoglycemia (especially in combination with insulin or sulfonylureas)
Less common but worth knowing:
- Pancreatitis (small absolute risk; ~0.3% per year)
- Gallstones during rapid weight loss
- Acid reflux
- Tachycardia (mild resting heart rate increase)
- Acute kidney injury secondary to severe vomiting
Rare but serious:
- Severe allergic reaction
- Possible thyroid C-cell tumors (rodent finding; human signal unclear)
- Suicidal ideation (post-market reports; FDA reviewed and found no causal link in 2024)
The titration schedule reduces side-effect intensity but doesn't eliminate them. About 9.8% of patients on Saxenda 3.0 mg discontinued due to adverse events in trials, vs 4.3% on placebo.
Liraglutide vs semaglutide vs tirzepatide
Three GLP-1 era options, side by side.
| Feature | Liraglutide | Semaglutide | Tirzepatide |
|---|---|---|---|
| Receptor activity | GLP-1 only | GLP-1 only | GLP-1 + GIP |
| Half-life | 13 hours | 7 days | 5 days |
| Frequency | Daily | Weekly | Weekly |
| Diabetes brand | Victoza | Ozempic | Mounjaro |
| Obesity brand | Saxenda | Wegovy | Zepbound |
| Mean weight loss (max dose, ~1 year) | 5 to 8% | 12 to 15% | 15 to 22% |
| Mean A1C reduction (max dose) | 1.0 to 1.3% | 1.5 to 1.8% | 2.0 to 2.5% |
| Cardiovascular benefit established | Yes (LEADER) | Yes (SUSTAIN-6, SELECT) | Pending (SURPASS-CVOT ongoing) |
| Pediatric approval | Yes (10+ for Victoza, 12+ for Saxenda) | No (12+ for Wegovy as of 2022) | No |
Practical takeaway: liraglutide is older, less potent, and less convenient than the weekly options. It still has a real role for pediatric patients (the only GLP-1 with broad pediatric approval), patients who tolerate weekly drugs poorly, and patients whose insurance specifically covers liraglutide but not the newer options.
Who should and shouldn't take liraglutide
Candidates:
- Adults with type 2 diabetes inadequately controlled on metformin or other oral agents
- Adults with BMI 30+ or BMI 27+ with weight-related comorbidity (Saxenda)
- Adolescents (12+) with obesity (Saxenda has FDA pediatric approval)
- Pediatric patients (10+) with type 2 diabetes (Victoza)
- Patients who prefer or require daily dosing for tolerance reasons
Should not take:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of severe hypersensitivity to liraglutide or any excipient
- Active or recent pancreatitis
- Severe gastroparesis
- Pregnancy (stop at least 2 months before trying to conceive)
- Type 1 diabetes
- Diabetic ketoacidosis treatment
Use with caution:
- Concurrent insulin therapy (hypoglycemia risk; insulin doses often need to drop)
- Concurrent sulfonylurea therapy (same reason)
- Severe renal impairment (limited data; monitoring required)
- Severe hepatic impairment (limited data)
- History of cholelithiasis (rapid weight loss raises gallstone risk)
A clinician should review medical history and labs (HbA1c, fasting glucose, basic metabolic panel, thyroid screening) before starting liraglutide.
Cost, generics, and savings programs
Brand-name list price (without insurance):
- Victoza: approximately $900 to $1,000 per month
- Saxenda: approximately $1,300 to $1,400 per month
With insurance:
- Victoza copay: typically $25 to $300 per month for type 2 diabetes coverage
- Saxenda copay: highly variable; many plans don't cover obesity medications at all
- Manufacturer copay savings card available for eligible commercial-insurance patients
Generic and biosimilar options:
- A generic liraglutide (Liraglutide Hospira) was approved by the FDA in 2024 and reached limited commercial availability through 2025.
- Generic liraglutide pricing as of early 2026 is approximately $400 to $700 per month, still higher than expected because the launch has been slow.
- The generic is FDA-approved and bioequivalent to Victoza.
Compounded liraglutide: Some compounding pharmacies prepared liraglutide during periods of brand-name shortage. Compounded liraglutide is less common than compounded semaglutide or tirzepatide because liraglutide isn't typically on the FDA shortage list. If a compounded version is offered, the standard caveats apply: it's not FDA-approved, prepared by a state-licensed compounding pharmacy in response to an individual prescription.
What happens when you stop
Like all GLP-1 medications, the effects fade quickly after stopping liraglutide. The 13-hour half-life means the drug is essentially gone from the body within 3 days of the last dose.
SCALE Maintenance trial (Wadden et al., International Journal of Obesity, 2013): Patients lost an average of 6% body weight on liraglutide 3.0 mg over a year. After stopping, they regained about half of that loss within 12 months without active behavior change.
The pattern matches every other GLP-1 medication. The drug suppresses appetite while you're on it. When the drug is gone, appetite returns. Sustained weight loss after stopping requires established behavior change in eating, exercise, sleep, and stress management. For some patients, the medication window is enough to build those habits. For others, lifelong therapy is the practical approach.
Discontinuation should be planned, not abrupt. A short taper isn't required (the drug self-tapers over 3 days because of its short half-life), but provider input on what comes next is recommended.
FAQ
What is liraglutide used for? Liraglutide is FDA-approved for type 2 diabetes (Victoza, 1.8 mg) and chronic weight management (Saxenda, 3.0 mg). It's also FDA-approved for type 2 diabetes in pediatric patients 10 and older (Victoza) and for obesity in adolescents 12 and older (Saxenda).
How is liraglutide different from semaglutide? Both are GLP-1 receptor agonists, but liraglutide has a 13-hour half-life (daily injection) while semaglutide has a 7-day half-life (weekly injection). Semaglutide produces more weight loss and A1C reduction in head-to-head trials. Liraglutide has broader pediatric approval.
How fast does liraglutide work? Appetite suppression often appears within the first week of titration. A1C improvement is measurable by week 4 and reaches a steady state by week 12. Weight loss is gradual; most patients see meaningful change by month 3 and maximum effect around month 6 to 12.
What are the side effects of liraglutide? Most common are nausea, diarrhea, constipation, vomiting, and headache, especially during titration. Less common but serious effects include pancreatitis, gallstones during rapid weight loss, and (very rarely) thyroid C-cell tumors (rodent data; human signal unclear).
Does liraglutide cause hair loss? Some patients experience telogen effluvium (a temporary diffuse shedding) during rapid weight loss on liraglutide or any GLP-1. This is from the caloric deficit, not the drug itself. It usually resolves within 6 to 9 months as weight stabilizes and protein intake supports hair regrowth.
Can I take liraglutide and metformin together? Yes. The combination is common and well-tolerated. The two drugs work through different mechanisms and produce additive A1C reduction without significantly increasing hypoglycemia risk. No dose adjustment of metformin is needed when adding liraglutide.
Is liraglutide available as a generic? Yes. The FDA approved generic liraglutide in 2024 (Liraglutide Hospira). Commercial availability has been limited but expanding through 2025 and 2026. Generic liraglutide is bioequivalent to Victoza and typically costs $400 to $700 per month, lower than the brand but higher than expected.
Can I switch from Victoza to Saxenda? Possibly, with provider direction. The two contain the same active ingredient at different maximum doses. A patient on Victoza 1.8 mg for diabetes who wants to add weight management may continue titration to Saxenda 3.0 mg under provider supervision. Insurance coverage often differs between the two indications.
Does liraglutide increase heart rate? Yes, slightly. Average resting heart rate increases by 2 to 4 beats per minute on liraglutide. The increase is more pronounced at the Saxenda 3.0 mg dose. The clinical significance for healthy adults is small. Patients with arrhythmia history should discuss with a cardiologist before starting.
Is liraglutide safe in pregnancy? No. Liraglutide should be discontinued at least 2 months before trying to conceive. Animal studies showed fetal harm. There's no human safety data supporting use during pregnancy. If pregnancy occurs while on liraglutide, the medication should be stopped immediately.
What's the difference between liraglutide for diabetes and liraglutide for weight loss? The molecule is the same. Victoza (max 1.8 mg) is approved for type 2 diabetes. Saxenda (max 3.0 mg) is approved for chronic weight management. The brand names reflect the dose strength and the FDA-approved indication. Both contain liraglutide and work through identical mechanisms.
Can I drink alcohol on liraglutide? You can, but tolerance is often reduced. Many patients report less alcohol enjoyment and faster intoxication on a GLP-1. The combination can also worsen nausea. Patients on insulin or sulfonylureas plus liraglutide need to be especially careful about hypoglycemia with alcohol.
How long can I stay on liraglutide? Long-term use is supported by published safety data of 5+ years. There's no automatic stop date. The medication is generally continued as long as it's effective and tolerated, similar to how blood pressure medications are continued indefinitely. Discontinuation usually leads to weight regain and worsening blood sugar.
Author / review note
Reviewed by the FormBlends Medical Team. References include the LEAD program publications (Garber et al., Lancet, 2009; Marre et al., Diabetic Medicine, 2009), the LEADER cardiovascular outcomes trial (Marso et al., New England Journal of Medicine, 2016), the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., New England Journal of Medicine, 2015), the SCALE Maintenance trial (Wadden et al., International Journal of Obesity, 2013), and the FDA prescribing information for Victoza and Saxenda (revised 2023).
Related guides
- Liraglutide Saxenda Guide Daily Injection
- Victoza Dose in 2026: The Daily Titration, the 1.2 vs 1.8 mg Decision, and How to Handle Missed Injections
- Is Saxenda a GLP-1? The Daily-Injection Pioneer of GLP-1 Weight Loss
- What Is Liraglutide? A Plain-Language Guide to the Daily GLP-1 Medication
- Victoza Dosing: Complete Guide to Liraglutide Injection Schedule and Titration
- Saxenda Dose Escalation Schedule Explained Simply
Sources
- The LEAD program publications (Garber et al., Lancet, 2009; Marre et al., Diabetic Medicine, 2009).
- The LEADER cardiovascular outcomes trial (Marso et al., New England Journal of Medicine, 2016).
- The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., New England Journal of Medicine, 2015).
- The SCALE Maintenance trial (Wadden et al., International Journal of Obesity, 2013).
- The FDA prescribing information for Victoza and Saxenda (revised 2023).
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Victoza and Saxenda are registered trademarks of Novo Nordisk A/S. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →